Medtronic plc (NYSE: MDT) adds to the robust data for its IN.PACT® Admiral® drug-coated balloon (DCB)  with the presentation of both its formal cost-effectiveness analysis from the U.S. cohort of the IN.PACT SFA Trial and clinical results from the in-stent restenosis cohort data from Medtronic's IN.PACT Global Study. 

Medtronic plc (NYSE: MDT) today announced new clinical data in interventional treatments for aortic and peripheral vascular diseases in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2015.

Sunnyvale, CA. -- Silk Road Medical, Inc. announced the 30 day outcomes from the ROADSTER IDE Study at the VIVA 2014 Vascular Interventional Advances Annual Conference in Las Vegas, Nevada. The trial studied the treatment of carotid artery stenosis with a new device and hybrid procedure combining the best elements of carotid endarterectomy (CEA) and carotid artery stenting (CAS).

Patients with peripheral artery disease (PAD) and diabetes who underwent treatment with a drug-coated balloon fared better than counterparts who received standard care, according to a subanalysis of the IN.PACT SFA trial.

At five years, the Zilver PTX stent proved to be a durable treatment for peripheral artery disease with sustained benefit, results presented Nov. 4 at the 2014 Vascular Interventional Advances (VIVA) meeting showed.

Shockwaves appear to have early success in breaking up calcified lesions safely. In research presented Nov. 5 at the 2014 Vascular Interventional Advances (VIVA) meeting in Las Vegas, a lithotripsy-with-balloon technique used on peripheral artery lesions resulted in all patients achieving less than 50 percent stenosis. 

Covidien announced 12-month results of the DEFINITIVE AR study, the first randomized study designed to identify the clinical benefits of plaque removal using directional atherectomy followed by drug coated balloon. The results were presented by Professor Thomas Zeller of the Universitaets-Herzzentrum, Bad Krozingen, Germany at the Vascular Interventional Advances (VIVA) 2014 conference in Las Vegas, Nev.

AccessClosure, Inc., the market leader in extravascular closure devices, announced today an exclusive agreement with Ostial Corporation to distribute the Flash Ostial System Dual Balloon Angioplasty Catheter in the United States. The Flash Ostial System is designed to help overcome the challenges of aorto-ostial stenting and compliments the Mynx® Product Family of Vascular Closure Devices to expand AccessClosure’s portfolio.